STOCK TITAN

[8-K] PARAMOUNT GROUP, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Form 4 filing for Kodiak Sciences Inc. (KOD) discloses that officer John A. Borgeson received a stock-option grant covering 250,000 shares of common stock on 07/04/2025 at an exercise price of $3.95 per share.

The option vests on a standard four-year schedule:

  • 1/48th (≈5,208 shares) vests one month after 07/01/2025
  • The remaining 47/48th vests in equal monthly installments thereafter, subject to continuous service

No shares were bought or sold outright; this is a new award that increases Borgeson’s potential ownership to 250,000 derivative securities held directly. The grant expires on 07/03/2035.

Investors should note that the award may create modest future dilution if exercised, but it also strengthens long-term alignment between the executive and shareholders.

Il modulo 4 per Kodiak Sciences Inc. (KOD) rivela che l’ufficiale John A. Borgeson ha ricevuto una concessione di opzioni su azioni per 250.000 titoli ordinari il 04/07/2025, con un prezzo di esercizio di 3,95 $ per azione.

L’opzione si consolida secondo un programma standard di quattro anni:

  • 1/48 (circa 5.208 azioni) si consolida un mese dopo il 01/07/2025
  • Il restante 47/48 si consolida in rate mensili uguali successivamente, subordinato al servizio continuativo

Non sono state acquistate o vendute azioni direttamente; si tratta di un nuovo premio che aumenta la potenziale proprietà di Borgeson a 250.000 titoli derivati detenuti direttamente. La concessione scade il 03/07/2035.

Gli investitori dovrebbero considerare che il premio potrebbe causare una modesta diluizione futura se esercitato, ma rafforza anche l’allineamento a lungo termine tra il dirigente e gli azionisti.

La presentación del Formulario 4 para Kodiak Sciences Inc. (KOD) revela que el ejecutivo John A. Borgeson recibió una concesión de opciones sobre acciones que cubre 250,000 acciones ordinarias el 04/07/2025, con un precio de ejercicio de $3.95 por acción.

La opción se consolida según un calendario estándar de cuatro años:

  • 1/48 (aproximadamente 5,208 acciones) se consolida un mes después del 01/07/2025
  • El restante 47/48 se consolida en cuotas mensuales iguales posteriormente, sujeto a servicio continuo

No se compraron ni vendieron acciones directamente; este es un nuevo premio que aumenta la propiedad potencial de Borgeson a 250,000 valores derivados mantenidos directamente. La concesión expira el 03/07/2035.

Los inversores deben tener en cuenta que el premio puede generar una dilución futura modesta si se ejerce, pero también fortalece la alineación a largo plazo entre el ejecutivo y los accionistas.

Kodiak Sciences Inc. (KOD)의 Form 4 제출에 따르면 임원 John A. Borgeson이 2025년 7월 4일에 보통주 250,000주에 대한 스톡옵션 부여를 받았으며, 행사가격은 주당 $3.95입니다.

옵션은 표준 4년 일정에 따라 권리가 부여됩니다:

  • 2025년 7월 1일 기준 한 달 후 1/48(약 5,208주)이 권리 발생
  • 나머지 47/48은 지속적인 근무 조건 하에 매월 동일한 비율로 권리 발생

직접 주식을 매수하거나 매도한 것은 아니며, 이는 Borgeson의 잠재적 소유권을 250,000개의 파생증권으로 증가시키는 새로운 부여입니다. 이 부여는 2035년 7월 3일에 만료됩니다.

투자자들은 이 부여가 행사 시 다소의 미래 희석 효과를 발생시킬 수 있지만, 임원과 주주 간의 장기적인 이해관계 일치를 강화한다는 점을 유념해야 합니다.

Le dépôt du formulaire 4 pour Kodiak Sciences Inc. (KOD) révèle que le dirigeant John A. Borgeson a reçu une attribution d’options d’achat portant sur 250 000 actions ordinaires le 04/07/2025, avec un prix d’exercice de 3,95 $ par action.

L’option se libère selon un calendrier standard de quatre ans :

  • 1/48 (environ 5 208 actions) se libère un mois après le 01/07/2025
  • Les 47/48 restants se libèrent par versements mensuels égaux ensuite, sous réserve de service continu

Aucune action n’a été achetée ou vendue directement ; il s’agit d’une nouvelle attribution qui augmente la détention potentielle de Borgeson à 250 000 titres dérivés détenus directement. L’attribution expire le 03/07/2035.

Les investisseurs doivent noter que cette attribution pourrait entraîner une dilution modérée future en cas d’exercice, mais elle renforce également l’alignement à long terme entre le dirigeant et les actionnaires.

Formular 4 Einreichung für Kodiak Sciences Inc. (KOD) offenbart, dass der Offizier John A. Borgeson am 04.07.2025 eine Aktienoptionszuteilung über 250.000 Stammaktien zu einem Ausübungspreis von 3,95 $ pro Aktie erhalten hat.

Die Option wird nach einem standardmäßigen Vierjahresplan erworben:

  • 1/48 (ca. 5.208 Aktien) wird einen Monat nach dem 01.07.2025 erworben
  • Die verbleibenden 47/48 werden danach in gleichen monatlichen Raten erworben, vorbehaltlich fortlaufender Dienstzeit

Es wurden keine Aktien direkt gekauft oder verkauft; dies ist eine neue Zuteilung, die Borgesons potenziellen Besitz auf 250.000 derivative Wertpapiere direkt erhöht. Die Zuteilung läuft am 03.07.2035 ab.

Investoren sollten beachten, dass die Zuteilung bei Ausübung zu einer moderaten zukünftigen Verwässerung führen kann, aber auch die langfristige Ausrichtung zwischen dem Geschäftsführer und den Aktionären stärkt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine option grant; aligns incentives, limited immediate impact; modest future dilution possible.

The Form 4 shows a single compensatory grant rather than an open-market transaction. At 250,000 options, the award is meaningful for the individual but immaterial relative to Kodiak’s total shares outstanding. The four-year, monthly vesting schedule is standard and promotes retention. No cash outflow or insider sentiment signal is present because no shares were purchased or sold. Potential dilution equals 250,000 shares, but that is minor unless numerous similar grants accumulate. Overall, governance practices appear conventional and shareholder-friendly.

Il modulo 4 per Kodiak Sciences Inc. (KOD) rivela che l’ufficiale John A. Borgeson ha ricevuto una concessione di opzioni su azioni per 250.000 titoli ordinari il 04/07/2025, con un prezzo di esercizio di 3,95 $ per azione.

L’opzione si consolida secondo un programma standard di quattro anni:

  • 1/48 (circa 5.208 azioni) si consolida un mese dopo il 01/07/2025
  • Il restante 47/48 si consolida in rate mensili uguali successivamente, subordinato al servizio continuativo

Non sono state acquistate o vendute azioni direttamente; si tratta di un nuovo premio che aumenta la potenziale proprietà di Borgeson a 250.000 titoli derivati detenuti direttamente. La concessione scade il 03/07/2035.

Gli investitori dovrebbero considerare che il premio potrebbe causare una modesta diluizione futura se esercitato, ma rafforza anche l’allineamento a lungo termine tra il dirigente e gli azionisti.

La presentación del Formulario 4 para Kodiak Sciences Inc. (KOD) revela que el ejecutivo John A. Borgeson recibió una concesión de opciones sobre acciones que cubre 250,000 acciones ordinarias el 04/07/2025, con un precio de ejercicio de $3.95 por acción.

La opción se consolida según un calendario estándar de cuatro años:

  • 1/48 (aproximadamente 5,208 acciones) se consolida un mes después del 01/07/2025
  • El restante 47/48 se consolida en cuotas mensuales iguales posteriormente, sujeto a servicio continuo

No se compraron ni vendieron acciones directamente; este es un nuevo premio que aumenta la propiedad potencial de Borgeson a 250,000 valores derivados mantenidos directamente. La concesión expira el 03/07/2035.

Los inversores deben tener en cuenta que el premio puede generar una dilución futura modesta si se ejerce, pero también fortalece la alineación a largo plazo entre el ejecutivo y los accionistas.

Kodiak Sciences Inc. (KOD)의 Form 4 제출에 따르면 임원 John A. Borgeson이 2025년 7월 4일에 보통주 250,000주에 대한 스톡옵션 부여를 받았으며, 행사가격은 주당 $3.95입니다.

옵션은 표준 4년 일정에 따라 권리가 부여됩니다:

  • 2025년 7월 1일 기준 한 달 후 1/48(약 5,208주)이 권리 발생
  • 나머지 47/48은 지속적인 근무 조건 하에 매월 동일한 비율로 권리 발생

직접 주식을 매수하거나 매도한 것은 아니며, 이는 Borgeson의 잠재적 소유권을 250,000개의 파생증권으로 증가시키는 새로운 부여입니다. 이 부여는 2035년 7월 3일에 만료됩니다.

투자자들은 이 부여가 행사 시 다소의 미래 희석 효과를 발생시킬 수 있지만, 임원과 주주 간의 장기적인 이해관계 일치를 강화한다는 점을 유념해야 합니다.

Le dépôt du formulaire 4 pour Kodiak Sciences Inc. (KOD) révèle que le dirigeant John A. Borgeson a reçu une attribution d’options d’achat portant sur 250 000 actions ordinaires le 04/07/2025, avec un prix d’exercice de 3,95 $ par action.

L’option se libère selon un calendrier standard de quatre ans :

  • 1/48 (environ 5 208 actions) se libère un mois après le 01/07/2025
  • Les 47/48 restants se libèrent par versements mensuels égaux ensuite, sous réserve de service continu

Aucune action n’a été achetée ou vendue directement ; il s’agit d’une nouvelle attribution qui augmente la détention potentielle de Borgeson à 250 000 titres dérivés détenus directement. L’attribution expire le 03/07/2035.

Les investisseurs doivent noter que cette attribution pourrait entraîner une dilution modérée future en cas d’exercice, mais elle renforce également l’alignement à long terme entre le dirigeant et les actionnaires.

Formular 4 Einreichung für Kodiak Sciences Inc. (KOD) offenbart, dass der Offizier John A. Borgeson am 04.07.2025 eine Aktienoptionszuteilung über 250.000 Stammaktien zu einem Ausübungspreis von 3,95 $ pro Aktie erhalten hat.

Die Option wird nach einem standardmäßigen Vierjahresplan erworben:

  • 1/48 (ca. 5.208 Aktien) wird einen Monat nach dem 01.07.2025 erworben
  • Die verbleibenden 47/48 werden danach in gleichen monatlichen Raten erworben, vorbehaltlich fortlaufender Dienstzeit

Es wurden keine Aktien direkt gekauft oder verkauft; dies ist eine neue Zuteilung, die Borgesons potenziellen Besitz auf 250.000 derivative Wertpapiere direkt erhöht. Die Zuteilung läuft am 03.07.2035 ab.

Investoren sollten beachten, dass die Zuteilung bei Ausübung zu einer moderaten zukünftigen Verwässerung führen kann, aber auch die langfristige Ausrichtung zwischen dem Geschäftsführer und den Aktionären stärkt.

0001605607false00016056072025-07-012025-07-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 1, 2025

 

Paramount Group, Inc.

(Exact Name of Registrant as Specified in its Charter)

Maryland

001-36746

32-0439307

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

1633 Broadway

New York, New York

10019

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (212) 237-3100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2.):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each Class

Trading Symbol

Name of each exchange on which registered

Common stock of Paramount Group, Inc., $0.01 par value per share

PGRE

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

 

 

As previously disclosed on a Form 8-K filed with the Securities and Exchange Commission on May 19, 2025, Paramount Group, Inc. (the “Company” or “Paramount Group”) announced that Wilbur Paes, the Company’s Chief Operating Officer, Chief Financial Officer and Treasurer would leave his position with the Company and/or the Company’s affiliates or subsidiaries, effective May 15, 2025 (the “Separation Date”).

 

In connection with Mr. Paes’s departure, on July 1, 2025, the Company, Paramount Group Management LP and Paramount Group Operating Partnership LP (the “Operating Partnership”) (collectively, the “Company Group”) and Mr. Paes executed a Separation Agreement and Release (the “Separation Agreement”). Pursuant to the Separation Agreement, and consistent with the terms of the second amended and restated employment agreement dated March 10, 2025 between the Company Group and Mr. Paes (the “Employment Agreement”), Mr. Paes will receive a single lump sum payment, less applicable tax-related deductions and withholdings, consisting of (i) a payment of $2,050,000 (representing one year of base salary plus an amount equal to the average of the annual incentive compensation paid to Mr. Paes in the last three fiscal years), (ii) a payment equal to his pro-rata annual incentive compensation for 2025 of $371,712, and (iii) a health care payment of $73,011.

 

In addition, Mr. Paes’s units in the Operating Partnership consisting of (i) 817,187 service-based long-term incentive plan units (“LTIP Units”), (ii) 227,825 service-based appreciation only LTIP Units (“AOLTIP Units”), and (iii) 40,525 performance-based LTIP units that are earned but still subject to service-based vesting conditions have vested or will vest in accordance with the terms of the Employment Agreement or the Separation Agreement, as applicable.

 

Mr. Paes will also remain eligible to earn a pro-rata portion of 450,282 performance-based LTIP Units and 1,621,973 performance-based AOLTIP Units subject to the attainment of performance vesting conditions at the end of the applicable performance period.

 

Pursuant to the Employment Agreement, Mr. Paes will remain subject to certain restrictive covenants, including non-solicitation, non-interference, and non-competition covenants. Additionally, pursuant to the Separation Agreement, Mr. Paes and the Company Group have agreed to a general release of claims.

 

The summary of the Separation Agreement set forth above is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

 

 


 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

 

 

 

 

 

 

Exhibit
Number

Description

 

10.1

 

 

Separation Agreement and Release among Paramount Group, Inc., Paramount Group Management LP, Paramount Group Operating Partnership LP and Wilbur Paes.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PARAMOUNT GROUP, INC.

 

 

 

Date: July 8, 2025

     By:

/s/ Timothy Dembo

 

     Name:

Timothy Dembo

 

     Title

Senior Vice President, General Counsel and Secretary

 

 

 

 

 


Paramount Group Inc

NYSE:PGRE

PGRE Rankings

PGRE Latest News

PGRE Latest SEC Filings

PGRE Stock Data

1.32B
184.49M
15.96%
66.95%
1.65%
REIT - Office
Real Estate Investment Trusts
Link
United States
NEW YORK